Spots Global Cancer Trial Database for rasburicase
Every month we try and update this database with for rasburicase cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome | NCT04745910 | Hematopoietic a... Malignant Solid... Tumor Lysis Syn... | Pegloticase Rasburicase | 18 Years - | M.D. Anderson Cancer Center | |
| Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma | NCT00199043 | Adult Acute Lym... High-grade Lymp... | Allopurinol Rasburicase | 15 Years - | Goethe University | |
| Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma | NCT00199043 | Adult Acute Lym... High-grade Lymp... | Allopurinol Rasburicase | 15 Years - | Goethe University | |
| Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies | NCT01564277 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Contiguous Stag... de Novo Myelody... Noncontiguous S... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Adult... Stage I Adult B... Stage III Adult... Stage IV Adult ... Untreated Adult... Untreated Adult... | rasburicase allopurinol | 18 Years - | Roswell Park Cancer Institute | |
| Rasburicase in Patients at Risk for Tumor Lysis Syndrome | NCT00628628 | Tumor Lysis Syn... | As Needed Rasbu... Fixed Dose Rasb... | - | M.D. Anderson Cancer Center | |
| Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS | NCT00360438 | Leukemia Lymphoma Tumor Lysis Syn... | Rasburicase | 18 Years - | M.D. Anderson Cancer Center | |
| Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2 | NCT01200485 | Leukemia Lymphoma | Rasburicase Allopurinol | - | M.D. Anderson Cancer Center | |
| Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS | NCT00360438 | Leukemia Lymphoma Tumor Lysis Syn... | Rasburicase | 18 Years - | M.D. Anderson Cancer Center | |
| Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients | NCT00186940 | Leukemia Lymphoma Tumor Lysis Syn... Hyperuricemia | Rasburicase | - | St. Jude Children's Research Hospital | |
| Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients | NCT00186940 | Leukemia Lymphoma Tumor Lysis Syn... Hyperuricemia | Rasburicase | - | St. Jude Children's Research Hospital | |
| Rasburicase in Tumor Lysis Syndrome | NCT00302653 | Hyperuricemia | Rasburicase | - 18 Years | Sanofi | |
| Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma | NCT00199043 | Adult Acute Lym... High-grade Lymp... | Allopurinol Rasburicase | 15 Years - | Goethe University | |
| Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma | NCT00057811 | Childhood Burki... Childhood Diffu... Childhood Immun... Stage I Childho... Stage I Childho... Stage II Childh... Stage II Childh... Stage III Child... Stage III Child... Stage IV Childh... Stage IV Childh... Untreated Child... | doxorubicin hyd... cyclophosphamid... methotrexate rasburicase leucovorin calc... prednisone methylprednisol... filgrastim rituximab cytarabine etoposide vincristine sul... hydrocortisone ... laboratory biom... | 1 Year - 29 Years | Children's Oncology Group | |
| Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS | NCT00360438 | Leukemia Lymphoma Tumor Lysis Syn... | Rasburicase | 18 Years - | M.D. Anderson Cancer Center | |
| Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome | NCT00563771 | Hyperuricemia | Rasburicase | - 18 Years | Sanofi |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
